WALL, N.J., Aug. 29, 2011 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (OTCBB:BKYI), a global leader in finger biometric identification technology solutions, today announced that the company will be presenting the latest innovations for the Apple iPad and Apple iPhone at the Allscripts Client Experience (ACE) August 29 – 31st 2011. The ACE event will be held at the Gaylord Opryland, in Nashville TN.
The new Allscripts was formed in August 2010 by the merger of Allscripts Healthcare Solutions, Inc. with the Eclipsys Corporation, creating the largest connected community of clients in healthcare. ACE offers two and a half days of educational sessions and networking opportunities presenting an ideal forum to demonstrate how the new iFMID (iOS Fingerprint Mobile Identification Device) for the iPad & iPhone can increase security, performance, compliance and convenience for healthcare providers accessing EMR & EHR records.
"The opportunity to introduce fingerprint authentication solutions for the iPad and iPhone at ACE could not be timelier. BIO-key is committed to providing advanced solutions for EMR & EHR providers; BIO-key software meets the new DEA ePrescription compliance guidelines and the 2 factor requirements of the Ohio Board of Pharmacy. Recently, upon presenting the new technology to an R&D manager at a leading EMR provider, he responded by saying BIO-key has hit a homerun for EMR providers with the new iPad solution," stated Randy Fodero, VP of Sales, BIO-key International Inc.
iFMID technology was developed by S.I.C. Biometrics, a Montreal Canada hardware and software technology company. S.I.C. designs, manufactures and internationally commercializes biometrics security products. On August 15, 2011, BIO-key International Inc. announced plans to acquire S.I.C. (Refer to the company website for more details about the planned acquisition. http://www.bio-key.com)
"Healthcare facilities and their staffs have aggressively adopted utilization of the iPad, because of its outstanding imaging capabilities and portability. With the introduction of iFMID technology, BIO-key is enabling users to authenticate using state of the art fingerprint biometric technology. Moving forward, healthcare professionals will be able to securely and compliantly log on to enterprise applications on their iPad by simply offering their fingerprint; a measurable improvement of the current password process," said Ben Hammel, Director of Identity Management Solutions, BIO-key International Inc.
About S.I.C. Biometrics
S.I.C Biometrics Inc. located in Montreal Canada, develops and manufacturers biometric plug-in mobile fingerprint scanners, biometric proximity cards and access control solutions. S.I.C. Biometrics through direct collaboration with Apple in 2009 is credited with developing the first fingerprint reader for the Apple iPad and iPhone. The S.I.C platform of identification solutions is interoperable and can be utilized with most existing infrastructures providing an optimum return on your investment. The company model of manufacturing simple and convenient turn-key solutions enables secure access to any IT application using state of the art finger biometric technology and is championed by S.I.C's FMID mobile solution product line. (http://www.sicbiometrics.com)
About BIO-key
BIO-key International, Inc., headquartered in Wall, New Jersey, develops and delivers advanced identification solutions to commercial and government enterprises, integrators, and custom application developers. BIO-key's award winning, high performance, scalable, cost-effective and easy-to-deploy biometric finger identification technology accurately identifies and authenticates users of wireless and enterprise applications. Our solutions are used in local embedded OEM products as well as some of the world's largest identification deployments to improve security, guarantee identity, and help reduce identity theft. BIO-key's technology is offered directly or by market leading partners around the world. (http://www.bio-key.com)
BIO-key Safe Harbor Statement
Certain statements contained in this press release may be construed as "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue, our ability to develop new products and evolve existing ones, the impact on our business of the recent financial crisis in the global capital markets and negative global economic trends, and our ability to attract and retain key personnel. For a more complete description of these and other risk factors that may affect the future performance of BIO-key International, Inc., see "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and its other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company also undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.